Cancer drug dasatinib shows promise in early HIV control trial
NCT ID NCT05527418
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests whether dasatinib, a drug currently used for leukemia, can safely control HIV in people who were infected within the past 3 to 12 months and have not yet taken standard HIV medications. Participants receive either dasatinib or a placebo for 16 weeks. The goal is to see if dasatinib can lower the amount of virus in the blood and reduce the hidden viral reservoirs that make HIV hard to cure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- dasatinib
- What this could lead to
- If successful, dasatinib might offer a new way to control HIV early after infection, possibly reducing the need for lifelong antiretroviral therapy.
- What could go wrong
- This is a small, early-phase trial. Dasatinib is a cancer drug with known side effects, and it may not effectively control HIV or reduce viral reservoirs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 to 65 years. * Documented asymptomatic HIV-1 infection of more than 3 months' duration (all patients must have a positive Western blot, including the p31 band whose appearance indicates infection of more than 90 days duration). * Not having received ART * CD4 T-lymphocyte count\> 350 / μl * Patient giving written informed consent Exclusion Criteria: * Active HBV (HBsAg+ or DNA+) and/or HCV (RNA+) infection in screening. * ALT\> 2 UNL, glomerular filtration rate \<70 mL / 1.73 m2, leukocytes \<4000 / mm3, total lymphocyte count \<1000 / mm3, platelets \<100,000 / mm3 or Hg \<12g / dL. * Pregnancy or active breastfeeding * Ongoing or previous pleural effusion * Chronic obstructive pulmonary disease, bronchial asthma or recent chest trauma. * History of gastrointestinal or other bleeding. * Any concomitant treatment with potentially dangerous drug interaction with dasatinib. * Any clinical condition, at the opinion of the investigator, contraindicating participation (for example, * Active neoplastic disease, active concomitant infection, etc.)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Recent HIV-1 infection are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eva Bonfill
Barcelona, Spain